Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 488.46% and ...

The drug and biotech sector saw a strong first half of 2024, driven by an increase in mergers and acquisitions (M&A), robust ...

The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or ...

AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...

Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...

Indianapolis: Eli Lilly and Company has announced that the European Medicines Agency's (EMA) Committee for Medicinal Products ...

The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target ...

(RTTNews) - Eli Lilly and Company (LLY) Friday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh for the treatment ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy ...

Eli Lilly (NYSE: LLY) has received a positive recommendation for approval from European regulators for its drug Omvoh in the ...

Eli Lilly said a key European regulatory committee has recommended expanded approval of its Omvoh drug for certain adults with the inflammatory bowel disorder Crohn's disease. Eli Lilly on Friday said ...

Eli Lilly (LLY) and Company announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a positive ...